Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.62 |
| ▸ | CASP1 | P29466 | 3/20 | 0.62 |
| ▸ | CASP7 | P55210 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27717859 | 0.90 | KDM4E (0.74) | ESR1ESR2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL10622340 | 0.88 | MEN1 (0.66) | ESR1ESR2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL29097426 | 0.84 | ESR1 (0.62) | ESR1ESR2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL7198305 | 0.84 | ESR1 (0.62) | ESR1ESR2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL28209379 | 0.83 | SMN1; SMN2 (0.62) | ESR1KDM4EALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL2181593 | 0.81 | ESR1 (0.59) | ESR1ESR2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL29239575 | 0.81 | KDM4E (0.63) | ESR1ESR2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11097926 | 0.80 | ESR1 (0.73) | ESR1ESR2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2181196 | 0.80 | KDM4E (0.72) | ESR1ESR2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL6261164 | 0.80 | ESR1 (0.58) | ESR1ESR2KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002092776-A2 | METHODS FOR THE INDENTIFICATION OF INHIBITORS OF 2-HYDROXYISOFLAVONE REDUCTASE EXPRESSION OR ACTIVITY IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2002-11-21 | — | — | WO | claimed |
| CN-119639835-A | Preparation method of keemun camellia seed fermented oil | 广州中妆美业化妆品有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240245741-A1 | EXTRACTION METHOD USING AN AQUEOUS ALKANEDIOL | MINASOLVE SAS (FR) | 2024-07-25 | — | — | US | disclosed |
| EP-4401852-A1 | EXTRACTION METHOD USING AN AQUEOUS ALKANEDIOL | Minasolve SAS (FR) | 2024-07-24 | — | — | EP | disclosed |
| US-20240116875-A1 | RATIONAL DESIGN, OPTIMIZATION, AND BIOLOGICAL EVALUATION OF NOVEL MEK4 INHIBITORS AGAINST PANCREATIC ADENOCARCINOMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-11 | — | — | US | disclosed |
| CN-117813017-A | Method for improving intestinal microbiota diversity | 雀巢产品有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117531228-A | Use of coconut water as extraction solvent | 巴斯夫美容护理法国公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117337167-A | Compositions and methods relating to hair loss | 阿拉斯廷护肤品股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230390355-A1 | COMPOSITIONS AND METHODS RELATING TO ALOPECIA | ALASTIN Skincare, Inc. (US) | 2023-12-07 | — | — | US | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-2672964-A1 | COMPOSITION FOR USE IN THE TREATMENT OF MENOPAUSE PROBLEMS/DISORDERS AND IN THE TREATMENT OF GENERAL AGING OF THE ORGANISM | Paladin Pharma S.p.A. (IT) | 2013-12-18 | — | — | EP | disclosed |
| JP-2013540422-A | — | — | 2013-11-07 | — | — | JP | disclosed |
| EP-2592951-A1 | NUTRACEUTICAL COMPOSITION OBTAINED FROM FUNGUS-CHALLENGED SOY SEEDLINGS | Frutarom Switzerland Ltd (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2592951-A1 | NUTRACEUTICAL COMPOSITION OBTAINED FROM FUNGUS-CHALLENGED SOY SEEDLINGS | Frutarom Switzerland Ltd (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012107905-A1 | COMPOSITION FOR USE IN THE TREATMENT OF MENOPAUSE PROBLEMS/DISORDERS AND IN THE TREATMENT OF GENERAL AGING OF THE ORGANISM. | PALADIN PHARMA S.P.A. (IT) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012006750-A1 | NUTRACEUTICAL COMPOSITION OBTAINED FROM FUNGUS-CHALLENGED SOY SEEDLINGS | FRUTAROM SWITZERLAND LTD. (CH) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012006750-A1 | NUTRACEUTICAL COMPOSITION OBTAINED FROM FUNGUS-CHALLENGED SOY SEEDLINGS | FRUTAROM SWITZERLAND LTD. (CH) | 2012-01-19 | — | — | WO | disclosed |
| EP-1720986-A2 | PLANT ISOFLAVONOID HYDROXYLASES AND METHODS OF USE THEREOF | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005042747-A2 | PLANT ISOFLAVONOID HYDROXYLASES AND METHODS OF USE THEREOF | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2002092776-A2 | METHODS FOR THE INDENTIFICATION OF INHIBITORS OF 2-HYDROXYISOFLAVONE REDUCTASE EXPRESSION OR ACTIVITY IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116875-A1 | RATIONAL DESIGN, OPTIMIZATION, AND BIOLOGICAL EVALUATION OF NOVEL MEK4 INHIBITORS AGAINST PANCREATIC ADENOCARCINOMA | MAPK4, MAP4K3, MAP3K4 | ESR1 3426/4885ESR2 3913/4885KDM4E 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.